<DOC>
	<DOCNO>NCT01005797</DOCNO>
	<brief_summary>The purpose study determine new investigational drug call Panobinostat safe , tolerable obtain initial assessment efficacy , give combination Sorafenib treatment certain type lung cancer , kidney cancer soft tissue sarcoma .</brief_summary>
	<brief_title>Study Panobinostat Combination With Sorafenib Kidney , Soft Tissue Lung Cancers</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Male female patient age ≥ 18 year old 2 . ECOG Performance Status ≤ 2 3 . Ability provide write informed consent obtain prior participation study relate procedure perform 4 . Part A ( dose escalation ) : Histologically cytologically document metastatic renal cell carcinoma ( RCC ) histologic type , soft tissue sarcoma ( STS ) limit follow histology : angiosarcoma , liposarcoma , leiomyosarcoma , nonsquamous nonsmallcell lung carcinoma ( NSCLC ) . Parts B ( RCC ) C ( NSCLC ) D ( STS ) ( expand cohort ) . Patients RCC must progressive metastatic disease receive least one multikinase inhibitor ( e.g. , sorafenib/Nexavar sunitinib/Sutent ) , mTOR inhibitor ( e.g. , Temsirolimus ) . Patients STS must progressive disease receive least two therapeutic regimen ( firstline , secondline treatment ) . For patient metastatic NSCLC , must receive two standard therapeutic regimen ( firstline secondline treatment ) . In Part A , evaluable disease radiology and/or recognize serum tumor marker require . In Parts B , C , D measurable disease RECIST require 5 . Predicted life expectancy ≥ 12 week 6 . Patients may prior therapy , provide follow condition meet : Patients must recover treatment related toxicity ( exception alopecia ) ≤ CTC grade 1 ( fatigue , neurotoxicity grade 2 permissible stable &gt; 3 month ) prior registration . 1 . Chemotherapy : A minimum 5 predict halflives agent must elapse end treatment registration study . When halflives available principle 2 week daily medication 3 week agent give less frequently adopt , discussion principal investigator recommend . 2 . Radiation : Patients may prior radiation therapy exceed 25 % bone marrow reserve provide recovered acute , toxic effect radiotherapy prior registration . A minimum 7 day must elapse end radiotherapy nontarget lesion registration study ( minimum 28 day target lesion ) . 3 . Surgery : Previous surgery permit provide wound healing occur prior registration . 7 . Patients must meet follow laboratory criterion : Hematology : Neutrophil count &gt; 1500/mm3 Platelet count &gt; 100,000/mm3L Hemoglobin ≥ 9 g/dL Biochemistry : AST/SGOT ALT/SGPT ≤ 2.5 x upper limit normal ( ULN ) ≤ 5.0 x ULN transaminase elevation due disease involvement Serum bilirubin ≤ 1.5 x ULN Serum creatinine ≤ 2.0 x ULN 24hour creatinine clearance ≥ 50 ml/min Total serum calcium ( correct serum albumin ) ionize calcium ≥ LLN Serum potassium ≥ LLN Serum sodium ≥ LLN Serum albumin ≥ LLN 2.5 g/dl Patients elevate Alkaline Phosphatase due bone metastasis enrol 8 . INR &lt; 1.5 PT/PTT within normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR measure prior initiation sorafenib/LBH589 monitor least weekly , define local standard care , INR stable . LBH589 sorafenib may elevate INR coumadin derivative 9 . Patients must clinically euthyroid ( patient may thyroid hormone replacement ) ' 10 . Baseline MUGA ECHO must demonstrate LVEF ≥ low limit institutional normal 11 . Supportive therapy include bisphosphonates permissible . Previous use myeloid erythroid growth factor support permissible , within 2 week commencement study . Primary prophylactic use myeloid erythroid growth factor permit within study , intervention secondary prophylaxis permit instituted follow documentation ≥ grade 3 neutropenia ≥ grade 2 anemia ( hemoglobin ) 12 . Patient must accessible repeat dose followup 13 . Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 7 day first administration study treatment . must willing use two method contraception one barrier method study 3 month last study drug administration Exclusion criterion : 1 . NSCLC squamous histology . 2 . Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer 3 . Patients need valproic acid medical condition study within 5 day prior first LBH589 treatment 4 . Known suspected allergy sorafenib LBH589 5 . Impaired cardiac function include one following : Screening ECG QTc &gt; 450 msec prior enrollment study Patients congenital long QT syndrome History sustain ventricular tachycardia Any history ventricular fibrillation torsades de pointes Bradycardia define heart rate &lt; 50 beat per minute . Patients pacemaker heart rate ≥ 50 beat per minute eligible . Patients myocardial infarction unstable angina within 6 month study entry Congestive heart failure ( NY Heart Association class III IV ) Right bundle branch block leave anterior hemiblock ( bifasicular block ) 6 . Uncontrolled hypertension 7 . Concomitant use drug risk cause torsades de pointes ( See Appendix 1.1 ) 8 . Concomitant use CYP3A4 inhibitor ( See Appendix 1.2 ) 9 . Patients unresolved diarrhea &gt; CTCAE grade 1 10 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral LBH589 11 . Other concurrent severe and/or uncontrolled medical condition 12 . Patients undergone major surgery &lt; 4 week prior start study drug recover side effect therapy 13 . Concomitant use anticancer therapy radiation therapy 14 . Women pregnant breast feed woman childbearing potential ( WOCBP ) willing use double barrier method contraception study 3 month end treatment . One method contraception must barrier method . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 7 day first administration oral LBH589 15 . Male patient whose sexual partner WOCBP use double method contraception study 3 month end treatment . One method must condom 16 . Patients history another primary malignancy within 5 year curatively treat CIS cervix , basal squamous cell carcinoma skin 17 . Patients know positivity human immunodeficiency virus ( HIV ) ) hepatitis C ; baseline test HIV hepatitis C require 18 . Patients significant history noncompliance medical regimen inability grant reliable informed consent 19 . Symptomatic brain metastasis stable , require steroid , antiepileptic medication . 20 . Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . 21 . Pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 week first dose study drug . 22 . Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug . 23 . Serious nonhealing wound , ulcer , bone fracture . 24 . Use St. John 's Wort rifampin ( rifampicin ) . 25 . Any condition impair patient 's ability swallow whole pill . 26 . Active uncontrolled infection , serious illness medical condition could interfere patient 's ongoing participation study . 27 . Any condition , investigator 's opinion , would compromise safety patient feasibility complete study objective use patient . Note : Investigators must ensure patient enrol study available study procedure , include dosing , toxicity assessment follow ability understand requirement study provide sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Renal Cancer</keyword>
	<keyword>Non Small Cell Lung Cancer ( NSCLC )</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Soft tissue sarcoma</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Panobinostat</keyword>
</DOC>